• Advanced Magnetics Inc., of Cambridge, Mass., plans to offer about 2 million shares of common stock through a shelf registration statement in an underwritten public offering. The company also plans to grant underwriters a 30-day option to purchase up to an additional 292,500 shares to cover overallotments. Morgan Stanley & Co. Inc. is acting as the sole book-running manager, with UBS Securities serving as joint lead manager and Jefferies & Co. Inc. and ThinkEquity Partners LLC acting as co-managers. The company has not yet priced the offering. Its shares (NASDAQ:AMAG) closed at $59.10 Friday, up $3.38.

• Crucell NV, of Leiden, the Netherlands, was awarded contracts totaling more than $230 million for its Quinvaxem and Hepavax-Gene pediatric vaccines by supranational organizations. The contracts cover the next three years until 2009, with the awarded amount growing over those years. Quinvaxem, a fully liquid pentavalent vaccine, was co-developed by Novartis Vaccines and Diagnostics, a division of Basel, Switzerland-based Novartis AG, and combines antigens for protection against diphtheria, tetanus, pertussia, hepatitis B and Haemophilus influenzae Type B. Hepavax-Gene is a recombinant hepatitis B vaccine.

• Cytokinetics Inc., of South San Francisco, said results from an oral bioavailability study of CK-1827452, a cardiac myosin activator, in healthy volunteers supported advancement of an oral formulation into Phase II trials. The study was designed as an open-label, four-way crossover trial to investigate the bioavailability and the effects of food on the bioavailability of two oral formulations of CK-1827452. The company also is studying an intravenous formulation of the drug, and expects to start an international Phase II program late this year or early next year in patients with stable heart failure, ischemic heart disease, tachycardia, impaired renal function, acutely decompensated heart failure and in patients with chronic heart failure at increased risk for heart failure, death and hospital admission.

• Evotec AG, of Hamburg, Germany, said PerkinElmer Inc., of Boston, agreed to acquire its majority-owned subsidiary, Evotec Technologies GmbH, in a cash transaction valued at about €23 million (US$30.6 million). Evotec Technologies provides high content screening instruments and analysis software for determining the composition of cells and cell structure. The deal is expected to be completed in the first quarter.

• Monogram Biosciences Inc., of South San Francisco, said its collaborator, New York-based Pfizer Inc., plans to establish a multinational expanded access program to make its investigational CCR5 antagonist maraviroc available to HIV/AIDS patients who have limited treatment options due to resistance or intolerance. Monogram's co-receptor tropism assay, Trofile, was used for patient selection for maraviroc's development program, and the companies agreed to make Monogram's assay available for patient use on a global basis. Pfizer also confirmed plans to submit applications for maraviroc approval in both the U.S. and European Union following review of data from two ongoing Phase III studies.

• QLT USA Inc., of Fort Collins, Colo., a subsidiary of Vancouver, British Columbia-based QLT Inc., said Eligard 45-mg six-month formulation was approved in Germany. Eligard, a palliative treatment for advanced prostate cancer, will be marketed by QLT's European partner, Tokyo-based Astellas Pharma Inc. Eligard previously was approved in Germany and other European countries for the one-month 7.5-mg formulation and the three-month 22.5-mg formulation.

• Semafore Pharmaceuticals Inc., of Indianapolis, received a one-year $535,000 grant from the Cancer Treatment Research Foundation to support all patient-associated costs of Semafore's upcoming Phase I trial of SF1126, its lead PI3K inhibitor. The trail will assess safety, as well as pharmacokinetic and pharmacodynamic parameters in patients with relapsed solid cancers where PI3K and associated PTEN pathways play a potential role. Semafore also intends to conduct molecular marker and imaging studies to help determine the optimal dosage and biological activity of SF1126.

No Comments